Takeda Pharmaceuticals has reached a settlement of $13.6 million in response to allegations that it incentivized physicians to prescribe one of its antidepressants.
The settlement, announced on May 15, 2026, addresses concerns regarding the company's practices related to kickbacks.
This case highlights ongoing scrutiny within the pharmaceutical industry regarding the ethics of incentivizing medical prescriptions.